Primary central nervous system lymphoma: essential points in diagnosis and management

被引：0
作者：
Semra Paydas
机构：
[1] Cukurova University,Department of Medical Oncology, Faculty of Medicine
来源：
Medical Oncology | 2017年 / 34卷
关键词：
Primary central nervous system lymphoma; Pathogenesis; Prognosis; Management; Chemotherapy; Radiotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Primary central nervous system lymphoma (PCNSL) is an extra-nodal non-Hodgkin lymphoma. PCNSL is defined as lymphoma involving the brain, leptomeninges, eyes, or spinal cord without evidence of lymphoma outside the CNS. Treatment includes induction with chemotherapy and consolidation with whole-brain radiotherapy or high-dose chemotherapy supported by autologous stem cell transplantation. High-dose methotrexate is the most important drug in cases with PCNSL, and this drug will be used in combination with small molecules, BTK inhibitors, new monoclonal antibodies, and checkpoint blockers.
引用
收藏
相关论文
共 1490 条
[61]  
Thurnher MM(2003)Prognostic scoring system for primary CNS lymphomas: the international Extranodal Lymphoma Study Group experience J Clin Oncol 57 127-1248
[62]  
Rieger A(2016)The role of upfront autologous stem cell transplantation in high-risk younger patients with primary central nervous system lymphoma Br J Haematol 21 4489-3068
[63]  
Kleibl-Popov C(2006)Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model J Clin Oncol 84 1242-1884
[64]  
Settinek U(2016)A new prognostic model using absolute lymphocyte count in patients with primary central nervous systemlymphoma Eur J Cancer 31 3061-253
[65]  
Henk C(2016)ESMO Guidelines Committee Ann Oncol 22 40-2330
[66]  
Haberler C(2003)Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy J Clin Oncol 23 1875-701
[67]  
Schindler E(2015)Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma Neurology 9 243-387
[68]  
Fraser E(2013)Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202) J Clin Oncol 122 2318-1520
[69]  
Gruenberg K(2016)TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy Acta Neuropathol Commun 27 697-1047
[70]  
Rubenstein JL(2009)Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma Leukemia 106 383-e259
234567891011